Today, BioArctic AB (publ) revealed they have initiated a research and collaboration deal with Eli Lilly and Company. This partnership focuses on exploring a novel treatment, leveraging BioArctic's unique assets. BioArctic, listed on NASDAQ STOCKHOLM under BIOA B, aims to advance their innovative approach through this alliance.